Roche Gains With Tecentriq IMpower131 NSCLC Data, But For How Long?
Roche is "first to market" with Phase III Tecentriq data in first-line squamous NSCLC setting, but analysts note Merck and Bristol are not far behind.
You may also be interested in...
In Phase III KEYNOTE-407 of squamous NSCLC, Keytruda/chemo combo shows overall survival benefit, which was reassuring news for doctors – and investors – ahead of ASCO.
Cancer immunotherapy is once again set to dominate the upcoming American Society of Clinical Oncology annual meeting, with a continuing showdown for PD-1 inhibitors in lung cancer, a CAR-T battle, and disappointments for new IO classes.
Also, Bristol has filed its Opdivo/Yervoy IO combination in Europe for first-line NSCLC, including squamous and non-squamous disease, based on CheckMate 227 data; some analysts expect FDA will accept the same dataset.